Michael R Bubb, M.D.
ASO PROFESSOR
Teaching Profile
Courses Taught
2020,2023
BMS6635 Derm and Msk
2016,2018
MDT7200 Elect Top/Medicine
2018
MDT7090 Elective Topics
2018
BME7980 Research for Doctoral Dissertation
2009-2010
IDH4917 Undergrad Research
2021
PAS5020 Intro to Medicine 2
Board Certifications
-
Internal MedicineAmerican Board of Internal Medicine
Clinical Profile
Specialties
- Rheumatology
Areas of Interest
- Osteoarthritis
- Rheumatoid arthritis
- Systemic lupus erythematosus
Publications
2022
A clinician’s perspective on why the trial did not work: comment on the editorial by Merrill.
Arthritis & rheumatology (Hoboken, N.J.).
74(6):1092-1093
[DOI] 10.1002/art.42095.
[PMID] 35188713.
2021
Egg Consumption and Cardiovascular Risk: Limitations of Observational Data.
The American journal of medicine.
134(8)
[DOI] 10.1016/j.amjmed.2021.03.027.
[PMID] 34340753.
2021
Subgingival microbiome of deep and shallow periodontal sitesĀ in patients with rheumatoid arthritis: a pilot study.
BMC oral health.
21(1)
[DOI] 10.1186/s12903-021-01597-x.
[PMID] 33964928.
2020
Do Hydroxychloroquine Blood Levels and Dose Identify Different Populations at Risk of Retinopathy? Comment on the Article by Petri et al.
Arthritis & rheumatology (Hoboken, N.J.).
72(12):2165-2166
[DOI] 10.1002/art.41464.
[PMID] 32741122.
2020
The Mismatch of Nutrition and Lifestyle Beliefs and Actions Among Physicians: A Wake-Up Call.
American journal of lifestyle medicine.
14(3):304-315
[DOI] 10.1177/1559827619883603.
[PMID] 32477033.
2019
Excess Deaths Upon Cessation of Xanthine Oxidase Inhibitor Treatment-Data From the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial: Comment on the Article by Choi et al.
Arthritis & rheumatology (Hoboken, N.J.).
71(8):1391-1392
[DOI] 10.1002/art.40914.
[PMID] 31022328.
2018
Does Digital Rectal Examination Reduce Subsequent Hospitalizations and Endoscopies or Vice Versa?
The American journal of medicine.
131(1)
[DOI] 10.1016/j.amjmed.2017.08.006.
[PMID] 29224615.
2018
Efficacy of Warfarin Anticoagulation and Incident Dementia: Does Cognitive Impairment Reduce Efficacy?
Mayo Clinic proceedings.
93(11)
[DOI] 10.1016/j.mayocp.2018.08.019.
[PMID] 30392551.
2016
In Reply I-Risk of Disseminated Disease in Immunosuppressed Patients Receiving Live Zoster Vaccine.
Mayo Clinic proceedings.
91(7)
[DOI] 10.1016/j.mayocp.2016.04.016.
[PMID] 27378041.
2016
Muscarinic type 3 receptor autoantibodies are associated with anti-SSA/Ro autoantibodies in Sjƶgren’s syndrome.
Journal of immunological methods.
437:28-36
[DOI] 10.1016/j.jim.2016.07.003.
[PMID] 27460476.
2016
Sjƶgren’s syndrome-associated microRNAs in CD14(+) monocytes unveils targeted TGFĪ² signaling.
Arthritis research & therapy.
18(1)
[DOI] 10.1186/s13075-016-0987-0.
[PMID] 27142093.
2015
Risk of Disseminated Varicella Zoster in Immunosuppressed Patients Receiving Zoster Vaccination.
Mayo Clinic proceedings.
90(11):1585-6
[DOI] 10.1016/j.mayocp.2015.09.001.
[PMID] 26541254.
2013
Anti-Th/To Antibodies in Various Systemic Rheumatic Diseases Screened By Anti-Rpp25 Elisa.
Arthritis and Rheumatism.
65:S287-S288
2013
Biochemical and biophysical properties of a putative hub protein expressed by vaccinia virus.
The Journal of biological chemistry.
288(16):11470-81
[DOI] 10.1074/jbc.M112.442012.
[PMID] 23476017.
2012
Clinical Features Associated With Anti-Th/To in Non-Scleroderma Patients – Sine Scleroderma?
Arthritis and Rheumatism.
64:S631-S632
2012
Potential, but unobserved, adverse cardiovascular effects from endurance exercise.
Mayo Clinic proceedings.
87(11):1133; author reply 1133-4
[DOI] 10.1016/j.mayocp.2012.08.011.
[PMID] 23127741.
2011
Atypical clinical presentation of a subset of patients with anti-RNA polymerase III–non-scleroderma cases associated with dominant RNA polymerase I reactivity and nucleolar staining.
Arthritis research & therapy.
13(4)
[DOI] 10.1186/ar3422.
[PMID] 21781293.
2011
Frequent coexistence of anti-topoisomerase I and anti-U1RNP autoantibodies in African American patients associated with mild skin involvement: a retrospective clinical study.
Arthritis research & therapy.
13(3)
[DOI] 10.1186/ar3334.
[PMID] 21569292.
2011
Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies.
Clinical rheumatology.
30(10):1333-9
[DOI] 10.1007/s10067-011-1751-0.
[PMID] 21523365.
2010
Changes in the Visiting Medical Student Clerkship Program at Mayo Clinic.
Mayo Clinic proceedings.
85(11):1060; author reply 1060-1
[DOI] 10.4065/mcp.2010.0566.
[PMID] 21037051.
2010
Identification of a cofilin-like actin-binding site on translationally controlled tumor protein (TCTP).
FEBS letters.
584(23):4756-60
[DOI] 10.1016/j.febslet.2010.10.054.
[PMID] 21036172.
2009
Air pollution and life expectancy.
The New England journal of medicine.
360(19):2032-3; author reply 2033
[DOI] 10.1056/NEJMc090375.
[PMID] 19420377.
2009
Exogenous thymosin beta4 prevents apoptosis in human intervertebral annulus cells in vitro.
Biotechnic & histochemistry : official publication of the Biological Stain Commission.
84(6):287-94
[DOI] 10.3109/10520290903116884.
[PMID] 20055734.
2009
Genetically elevated C-reactive protein and vascular disease.
The New England journal of medicine.
360(9):933-4; author reply 934
[PMID] 19256030.
2009
How depolymerization can promote polymerization: the case of actin and profilin.
BioEssays : news and reviews in molecular, cellular and developmental biology.
31(11):1150-60
[DOI] 10.1002/bies.200900049.
[PMID] 19795407.
2008
Clinical Significance of Autoantibodies To Topoisomerase I and Rna Polymerase Iii in An Unselected Rheumatic Disease Population
Arthritis and Rheumatism.
58:S372-S373
2008
Effect of profilin on actin critical concentration: a theoretical analysis.
Biophysical journal.
95(12):5544-73
[DOI] 10.1529/biophysj.108.134569.
[PMID] 18835900.
2008
Significant Racial and Gender Differences in Specificity of Scleroderma-Related Autoantibodies
Arthritis and Rheumatism.
58
2008
Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients.
Arthritis research & therapy.
10(4)
[DOI] 10.1186/ar2493.
[PMID] 18759964.
2007
Identification of single and double sites of phosphorylation by ECD FT-ICR/MS in peptides related to the phosphorylation site domain of the myristoylated alanine-rich C kinase protein.
Journal of the American Society for Mass Spectrometry.
18(12):2137-45
[PMID] 17962038.
2007
One-trial in vitro conditioning regulates an association between the beta-thymosin repeat protein Csp24 and actin.
Neuroscience.
148(2):413-20
[PMID] 17681698.
2007
Thymosin beta4: actin regulation and more.
Annals of the New York Academy of Sciences.
1112:76-85
[PMID] 17947588.
2006
A CapG gain-of-function mutant reveals critical structural and functional determinants for actin filament severing.
The EMBO journal.
25(19):4458-67
[PMID] 16977317.
2006
Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies.
Arthritis and rheumatism.
54(9):3051-6
[PMID] 16948135.
2006
Profilin: emerging concepts and lingering misconceptions.
Trends in biochemical sciences.
31(4):197-205
[PMID] 16542844.
2006
Tropomodulin 3 binds to actin monomers.
The Journal of biological chemistry.
281(47):36454-65
[PMID] 17012745.
2005
Interactions between vacuolar H+-ATPases and microfilaments in osteoclasts.
Journal of bioenergetics and biomembranes.
37(6):419-23
[PMID] 16691476.
2005
MARCKS is a natively unfolded protein with an inaccessible actin-binding site: evidence for long-range intramolecular interactions.
The Journal of biological chemistry.
280(11):9946-56
[PMID] 15640140.
2004
Actin crystal dynamics: structural implications for F-actin nucleation, polymerization, and branching mediated by the anti-parallel dimer.
Journal of structural biology.
146(3):291-301
[PMID] 15099571.
2004
Effects of profilin and thymosin beta4 on the critical concentration of actin demonstrated in vitro and in cell extracts with a novel direct assay.
The Journal of biological chemistry.
279(32):33519-27
[PMID] 15184365.
2004
Vacuolar H+-ATPase binding to microfilaments: regulation in response to phosphatidylinositol 3-kinase activity and detailed characterization of the actin-binding site in subunit B.
The Journal of biological chemistry.
279(9):7988-98
[PMID] 14662773.
2003
Depolymerization of actin filaments by profilin. Effects of profilin on capping protein function.
The Journal of biological chemistry.
278(27):24629-35
[PMID] 12730212.
2003
Regulation of endothelial nitric oxide synthase by the actin cytoskeleton.
American journal of physiology. Cell physiology.
284(6):C1542-9
[PMID] 12734108.
2003
Thymosin beta 4 interactions.
Vitamins and hormones.
66:297-316
[PMID] 12852258.
2002
Benzo(a)pyrene, but not 2,3,7,8-tetrachlorodibenzo-p-dioxin, alters cell adhesion proteins in human uterine RL95-2 cells.
Biochemical and biophysical research communications.
294(1):101-7
[PMID] 12054747.
2002
Control of actin dynamics by proteins made of beta-thymosin repeats: the actobindin family.
The Journal of biological chemistry.
277(17):14786-92
[PMID] 11856744.
2002
Polylysine induces an antiparallel actin dimer that nucleates filament assembly: crystal structure at 3.5-A resolution.
The Journal of biological chemistry.
277(23):20999-1006
[PMID] 11932258.
2001
Actin filament cross-linking by MARCKS: characterization of two actin-binding sites within the phosphorylation site domain.
The Journal of biological chemistry.
276(25):22351-8
[PMID] 11294839.
2001
Cytoskeletal regulation of the L-arginine/NO pathway in pulmonary artery endothelial cells.
American journal of physiology. Lung cellular and molecular physiology.
280(3):L465-73
[PMID] 11159030.
2000
Actin-latrunculin A structure and function. Differential modulation of actin-binding protein function by latrunculin A.
The Journal of biological chemistry.
275(36):28120-7
[PMID] 10859320.
2000
Effects of jasplakinolide on the kinetics of actin polymerization. An explanation for certain in vivo observations.
The Journal of biological chemistry.
275(7):5163-70
[PMID] 10671562.
1999
Active compression-decompression cardiopulmonary resuscitation.
The New England journal of medicine.
341(23)
[PMID] 10610451.
1999
Inclusion body myositis long after dermatomyositis: a report of two cases.
Clinical and experimental rheumatology.
17(2):235-9
[PMID] 10342053.
1999
Lengthening the second stalk of F(1)F(0) ATP synthase in Escherichia coli.
The Journal of biological chemistry.
274(51):36261-6
[PMID] 10593914.
1999
New anti-actin drugs in the study of the organization and function of the actin cytoskeleton.
Microscopy research and technique.
47(1):18-37
[PMID] 10506759.
1999
Phosphorylation-dependent conformational changes induce a switch in the actin-binding function of MARCKS.
The Journal of biological chemistry.
274(51):36472-8
[PMID] 10593944.
1999
Replacement of the aortic root in Marfan’s syndrome.
The New England journal of medicine.
341(19)
[PMID] 10577101.
1998
Formation of the b subunit dimer is necessary for interaction with F1-ATPase.
Biochemistry.
37(3):923-32
[PMID] 9454582.
1998
Localization of actobindin, profilin I, profilin II, and phosphatidylinositol-4,5-bisphosphate (PIP2) in Acanthamoeba castellanii.
Cell motility and the cytoskeleton.
39(2):134-46
[PMID] 9484955.
1998
Use of the F-actin-binding drugs, misakinolide A and swinholide A.
Methods in enzymology.
298:26-32
[PMID] 9751868.
1997
Gelsolin activates DNase I in vitro and cystic fibrosis sputum.
Biochemistry.
36(32):9637-41
[PMID] 9289015.
1997
Misakinolide A is a marine macrolide that caps but does not sever filamentous actin.
The Journal of biological chemistry.
272(12):7841-5
[PMID] 9065449.
1997
Profilin interacts with the Gly-Pro-Pro-Pro-Pro-Pro sequences of vasodilator-stimulated phosphoprotein (VASP): implications for actin-based Listeria motility.
Biochemistry.
36(27):8384-92
[PMID] 9204886.
1996
Assembly of MAP-2c and MTBR Fragments into Polymers Resembling Paired Helical Filaments
Journal of Biological Chemistry.
271:32702-32706
1996
In vitro polymerization of embryonic MAP-2c and fragments of the MAP-2 microtubule binding region into structures resembling paired helical filaments.
The Journal of biological chemistry.
271(51):32702-6
[PMID] 8955102.
1996
Self-assembly of the brain MAP-2 microtubule-binding region into polymeric structures resembling Alzheimer filaments.
Biochemical and biophysical research communications.
229(1):176-81
[PMID] 8954102.
1995
Kinetic model for the inhibition of actin polymerization by actobindin.
Biochemistry.
34(12):3921-6
[PMID] 7696256.
1995
Swinholide A is a microfilament disrupting marine toxin that stabilizes actin dimers and severs actin filaments.
The Journal of biological chemistry.
270(8):3463-6
[PMID] 7876075.
1994
Actobindin binds with high affinity to a covalently cross-linked actin dimer.
The Journal of biological chemistry.
269(41):25587-91
[PMID] 7929261.
1994
Actobindin induces the accumulation of actin dimers that neither nucleate polymerization nor self-associate.
The Journal of biological chemistry.
269(41):25592-7
[PMID] 7929262.
1994
Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin.
The Journal of biological chemistry.
269(21):14869-71
[PMID] 8195116.
1993
Rabbit skeletal muscle actin behaves differently than Acanthamoeba actin when added to soluble extracts of Acanthamoeba castellanii.
Biochemical and biophysical research communications.
196(2):569-75
[PMID] 8240329.
1992
Limited proteolysis reveals a structural difference in the globular head domains of dephosphorylated and phosphorylated Acanthamoeba myosin II.
The Journal of biological chemistry.
267(29):20905-8
[PMID] 1400405.
1992
Profilin-actin complexes directly elongate actin filaments at the barbed end.
Biochemistry.
31(6):1827-36
[PMID] 1737036.
1991
Purification of actobindin from Acanthamoeba castellanii.
Methods in enzymology.
196:119-25
[PMID] 1851935.
1991
The interaction of monomeric actin with two binding sites on Acanthamoeba actobindin.
The Journal of biological chemistry.
266(6):3820-6
[PMID] 1995634.
1991
The interfaces of actin and Acanthamoeba actobindin. Identification of a new actin-binding motif.
The Journal of biological chemistry.
266(23):15427-31
[PMID] 1869561.
1990
The covalent structure of Acanthamoeba actobindin.
The Journal of biological chemistry.
265(22):12801-5
[PMID] 2376577.
Grants
Jul 2023
ACTIVE
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATMENT IN STUDY PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Role: Principal Investigator
Funding: PAREXEL INTERNATIONAL CORP
via UCB BIOPHARMA SRL
Apr 2023
ACTIVE
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus
Role: Principal Investigator
Funding: DRUGDEV INC
via BRISTOL MYERS SQUIBB CO
Dec 2022
ACTIVE
A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants with Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)
Role: Principal Investigator
Funding: IQVIA
via BIOGEN MA INC
Dec 2022
ACTIVE
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy
Role: Principal Investigator
Funding: ICON CLINICAL RESEARCH INC
via ARGENX BVBA
Oct 2022
ACTIVE
A 52-week, randomized, double-blind, double-dummy, parallel-group,
multi-centre, non-inferiority study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy
Role: Principal Investigator
Funding: SYNEOS HEALTH
via GLAXO SMITHKLINE
Sep 2022
ACTIVE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults with Dermatomyositis
Role: Principal Investigator
Funding: PREMIER RESEARCH INTERNATIONAL
via PRIOVANT THERAPEUTICS
Jun 2022
ACTIVE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3
Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care
Role: Principal Investigator
Funding: BIOGEN MA INC
May 2022
ACTIVE
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (lgAN)
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC
via ALEXION PHARMACEUTICALS
Dec 2021
ACTIVE
A Phase 1b Randomized, Double-blind, Placebo-controlled, Multiple Ascending-dose Study of EQ001 in Subjects with Systemic Lupus Erythematosus with or without Active Proliferative Lupus Nephritis
Role: Principal Investigator
Funding: SYNEOS HEALTH
via EQUILLIUM
Aug 2021
ACTIVE
A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus Erythematosus
Role: Principal Investigator
Funding: PHARMACEUTICAL RES ASSO
via BRISTOL MYERS SQUIBB CO
May 2021
ACTIVE
A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of dapirolizumab pegol in study participants with moderately to severely active systemic lupus erythematosus
Role: Principal Investigator
Funding: PAREXEL INTERNATIONAL CORP
via UCB BIOPHARMA SRL
Mar 2021
ACTIVE
A Phase 1b, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of AEVI-007 in Subjects with Adult Onset Stills Disease
Role: Principal Investigator
Funding: PRA HEALTH SCIENCES
via CERECOR
Jan 2021
– Aug 2023
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Guselkumab in Subjects with Active Lupus Nephritis
Role: Principal Investigator
Funding: JANSSEN RESEARCH AND DEVELOPMENT
Jun 2020
ACTIVE
A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy
Role: Principal Investigator
Funding: GREENPHIRE
via AMGEN INC
Jul 2019
ACTIVE
A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 with Background Treatment in Subjects with Lupus Nephritis
Role: Principal Investigator
Funding: PHARMACEUTICAL RES ASSO
via BRISTOL MYERS SQUIBB CO
Apr 2019
ACTIVE
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects with Systemic Lupus Erythematosus
Role: Principal Investigator
Funding: PRA HEALTH SCIENCES
via BRISTOL MYERS SQUIBB CO
Mar 2019
ACTIVE
CTOA Bubb
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Oct 2018
– Oct 2023
A Phase 3, Multicenter, Randomized, Double-Blind, PlaceboControlled,104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination with a Single Cycle of Rituximab compared to Belimumab Monotherapy in Adult Subjects with Systemic Lupus Erythematosus (SLE)
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC
via GLAXO SMITHKLINE
Dec 2017
– Nov 2021
A Randomized, Double-Blind, Active Comparator-Controlled, Crossover Study to Assess the Capacity of Delayed-Release Prednisone (RAYOS?) Compared to Immediate-Release Prednisone to Improve Fatigue and Control Morning Symptoms in Subjects with Generalized Systemic Lupus Erythematosus
Role: Principal Investigator
Funding: AMPEL BIOSOLUTIONS
Dec 2017
– Dec 2022
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects with Lupus Membranous Nephropathy (LMN)
Role: Principal Investigator
Funding: ICON CLINICAL RESEARCH INC
via GILEAD SCIENCES
Jul 2017
– Jul 2022
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CC-220 in Subjects with Active Systemic Lupus Erythematosus
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC
via CELGENE CORP
May 2017
– Nov 2020
A PHASE 2A, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RSLV-132 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Role: Principal Investigator
Funding: RESOLVE THERAPEUTICS LLC
Feb 2017
– Mar 2022
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus standard of Care versus Placebo plus Standard of Care in Adult Subjects with Active Lupus Nephritis.
Role: Principal Investigator
Funding: IQVIA
via HUMAN GENOME SCIENCES
Jun 2016
ACTIVE
CLINICAL TRIAL NETWORK INFRASTRUCTURE GRANT AGREEMENT
Role: Principal Investigator
Funding: LUPUS THERAPEUTICS
Dec 2015
– Feb 2019
Oral Metagenomic Biomarkers in Rheumatoid Arthritis
Role: Project Manager
Funding: US ARMY MED RES ACQUISITION
Jun 2013
– Nov 2017
BLISS-LN
Role: Principal Investigator
Funding: IQVIA
via HUMAN GENOME SCIENCES
Sep 2012
– Dec 2016
Ethnic heterogeneity in microRNA expression as a biomarker in rheumatoid arthritis
Role: Project Manager
Funding: PFIZER INC
Education
Fellowship – Rheumatology
1992
·
N I H W G Magnuson
Residency – Internal Medicine
1989
·
Barnes Hospital
Medical Degree
1985
·
Johns Hopkins University
Contact Details
Phones:
- Business:
- (352) 265-4846
Emails:
- Business:
- bubbmr@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100221
GAINESVILLE FL 32610 - Business Street:
-
CG-97
GAINESVILLE FL 32611